Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Plain-language summary

Tau-like protein levels from 40 Down syndrome (DS) persons (31-70 years old), 40 non-DS age-matched normal controls, 18 non-DS mentally retarded (MR) persons (26-91 years old), 25 probable Alzheimer disease (AD) patients (55-99 years old) and 24 non-demented elderly controls (54-79 years old) were measured using a sandwich enzyme linked immunosorbent assay. The levels were detected in 22 of 40 DS persons and were significantly higher in DS than any other group (P < 0.0001). There was no relationship between tau-like protein levels and age, gender or apolipoprotein E phenotypes in any of the five groups.

What this study adds

Evidence grade: Low

Tau-like protein levels were significantly higher in 40 people with Down syndrome than in normal controls, mentally retarded persons, probable Alzheimer's disease patients, or non-demented elderly controls, and were detected in 22 of the 40. No relationship was found between these levels and age, gender, or apolipoprotein E phenotypes in any group.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mehta, P. D., Patrick, B. A., Dalton, A. J., Aisen, P. S., Emmerling, M. E., Sersen, E. A., et al. (1999). Increased levels of tau-like protein in patients with Down syndrome. Neuroscience letters. https://doi.org/10.1016/s0304-3940(99)00754-5

Vancouver

Mehta PD, Patrick BA, Dalton AJ, Aisen PS, Emmerling ME, Sersen EA, et al. Increased levels of tau-like protein in patients with Down syndrome. Neuroscience letters. 1999. doi:10.1016/s0304-3940(99)00754-5. PMID: 10580699.

BibTeX

@article{mehta1999-10580699,
  author  = {Mehta, P. D. and Patrick, B. A. and Dalton, A. J. and Aisen, P. S. and Emmerling, M. E. and Sersen, E. A. and Wisniewski, H. M.},
  title   = {{Increased levels of tau-like protein in patients with Down syndrome}},
  journal = {Neuroscience letters},
  year    = {1999},
  doi     = {10.1016/s0304-3940(99)00754-5},
  pmid    = {10580699},
  url     = {https://doi.org/10.1016/s0304-3940(99)00754-5}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

Tau-like protein levels were significantly higher in 40 people with Down syndrome than in normal controls, mentally retarded persons, probable Alzheimer's disease patients, or non-demented elderly controls, and were detected in 22 of the 40. No relationship was found between these levels and age, gender, or apolipoprotein E phenotypes in any group.

Study details

How this study scored 29/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 29 of 100.29 of 100 points earned71 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuroscience letters)
Journal's citation record 3 / 4 Neuroscience Letters: journal h-index 267 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1999 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.2 citations a year over 29 year(s) since 1999
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Henryk M. Wı́sniewski: h-index 76 (OpenAlex, whole career)
Institution's track record 0 / 3 Georgetown University Medical Center: institution h-index 564 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 10580699)
Free to read 0 / 2 Behind a paywall — scores zero
Total 29 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →